SARS-CoV-2 serosurvey across multiple waves of the COVID-19 pandemic in New York City between 2020-2023.

Autor: Carreño JM; Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.; Center for Vaccine Research and Pandemic Preparedness (C-VaRPP), Icahn School of Medicine at Mount Sinai, New York, NY, USA., Wagner AL; Department of Epidemiology, School of Public Health, University of Michigan, 1415 Washington Heights, Ann Arbor, MI, 48109, USA., Monahan B; Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.; Center for Vaccine Research and Pandemic Preparedness (C-VaRPP), Icahn School of Medicine at Mount Sinai, New York, NY, USA., Singh G; Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.; Center for Vaccine Research and Pandemic Preparedness (C-VaRPP), Icahn School of Medicine at Mount Sinai, New York, NY, USA., Floda D; Department of Genetics and Genomic Sciences, ISMMS, New York, NY, USA., Gonzalez-Reiche AS; Department of Genetics and Genomic Sciences, ISMMS, New York, NY, USA., Tcheou J; Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.; Center for Vaccine Research and Pandemic Preparedness (C-VaRPP), Icahn School of Medicine at Mount Sinai, New York, NY, USA., Raskin A; Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.; Center for Vaccine Research and Pandemic Preparedness (C-VaRPP), Icahn School of Medicine at Mount Sinai, New York, NY, USA., Bielak D; Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.; Center for Vaccine Research and Pandemic Preparedness (C-VaRPP), Icahn School of Medicine at Mount Sinai, New York, NY, USA., Morris S; Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.; Center for Vaccine Research and Pandemic Preparedness (C-VaRPP), Icahn School of Medicine at Mount Sinai, New York, NY, USA., Fried M; Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.; Center for Vaccine Research and Pandemic Preparedness (C-VaRPP), Icahn School of Medicine at Mount Sinai, New York, NY, USA., Yellin T; Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.; Center for Vaccine Research and Pandemic Preparedness (C-VaRPP), Icahn School of Medicine at Mount Sinai, New York, NY, USA., Sullivan L; Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.; Center for Vaccine Research and Pandemic Preparedness (C-VaRPP), Icahn School of Medicine at Mount Sinai, New York, NY, USA., Sordillo EM; Department of Pathology, Molecular and Cell Based Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA. Emilia.sordillo@mountsinai.org., Gordon A; Department of Epidemiology, School of Public Health, University of Michigan, 1415 Washington Heights, Ann Arbor, MI, 48109, USA. gordonal@umich.edu., van Bakel H; Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA. harm.vanbakel@mssm.edu.; Department of Genetics and Genomic Sciences, ISMMS, New York, NY, USA. harm.vanbakel@mssm.edu.; Icahn Genomics Institute, ISMMS, New York, NY, USA. harm.vanbakel@mssm.edu.; Department of Artificial Intelligence And Human Health, Icahn School of Medicine at Mount Sinai, New York, NY, USA. harm.vanbakel@mssm.edu., Simon V; Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA. viviana.simon@mssm.edu.; Center for Vaccine Research and Pandemic Preparedness (C-VaRPP), Icahn School of Medicine at Mount Sinai, New York, NY, USA. viviana.simon@mssm.edu.; Department of Pathology, Molecular and Cell Based Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA. viviana.simon@mssm.edu.; Division of Infectious Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA. viviana.simon@mssm.edu.; The Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA. viviana.simon@mssm.edu., Krammer F; Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA. florian.krammer@mssm.edu.; Center for Vaccine Research and Pandemic Preparedness (C-VaRPP), Icahn School of Medicine at Mount Sinai, New York, NY, USA. florian.krammer@mssm.edu.; Department of Pathology, Molecular and Cell Based Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA. florian.krammer@mssm.edu.; Ignaz Semmelweis Institute, Interuniversity Institute for Infection Research, Medical University of Vienna, Vienna, Austria. florian.krammer@mssm.edu.
Jazyk: angličtina
Zdroj: Nature communications [Nat Commun] 2024 Jul 11; Vol. 15 (1), pp. 5847. Date of Electronic Publication: 2024 Jul 11.
DOI: 10.1038/s41467-024-50052-2
Abstrakt: Sero-monitoring provides context to the epidemiology of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections and changes in population immunity following vaccine introduction. Here, we describe results of a cross-sectional hospital-based study of anti-spike seroprevalence in New York City (NYC) from February 2020 to July 2022, and a follow-up period from August 2023 to October 2023. Samples from 55,092 individuals, spanning five epidemiological waves were analyzed. Prevalence ratios (PR) were obtained using Poisson regression. Anti-spike antibody levels increased gradually over the first two waves, with a sharp increase during the 3rd wave coinciding with SARS-CoV-2 vaccination in NYC resulting in seroprevalence levels >90% by July 2022. Our data provide insights into the dynamic changes in immunity occurring in a large and diverse metropolitan community faced with a new viral pathogen and reflects the patterns of antibody responses as the pandemic transitions into an endemic stage.
(© 2024. The Author(s).)
Databáze: MEDLINE
Externí odkaz: